High-grade osteosarcoma is a malignant tumor of bone with diverse genomics, including mutations in TP53, RB1, FGFR1, IGF1R, and DNA structural alterations.4-7 In most sarcomas, including osteosarcoma, chemotherapy has traditionally been the backbone of therapy as there is an absence of classic kinase alterations as the main drivers (with exceptions such as GI stromal tumor [GIST], dermatofibrosarcoma protuberans, and inflammatory myofibroblastic tumor [IMT]). This evidence concerns the gene TP53 and inflammatory myofibroblastic tumor.